Menopause, the gut microbiome, and the science of what actually helps.
For decades, the conversation around menopause has centred on hot flushes and hormones. But a quieter crisis has been unfolding in the gut - one that affects the majority of women in midlife transition, shapes their mood, their weight, their bones, and their cardiovascular health, and is almost never addressed by the clinicians they turn to for help.
New research, presented at the 2025 Annual Meeting of The Menopause Society, confirms what many women have felt but been unable to name: that perimenopause and menopause trigger a profound and measurable disruption to the gut - and that the system most responsible for regulating oestrogen, inflammation, bone density, cognitive function, and metabolic health is the one that medicine has been slowest to address.
The scale of the problem
The data from The Menopause Society's 2025 Annual Meeting is striking. 82% of women report that gut symptoms begin or worsen at menopause. 55% say digestive problems significantly affect their quality of life. Of those who sought medical care, 58% found it inadequate - and 89% are left to self-manage through diet, supplements, or stress tools without professional guidance.
"I had tried so many different powders and supplements over the years. Nothing really moved the needle. The bloating was just constant - I'd accepted it as part of this stage of life. Within a few weeks of ID², something shifted. The bloating eased. I felt lighter, genuinely lighter - not just physically. It's the first thing that has felt different. Actually different."
- Orly, ID² Early Participant
The science of the disruption
The gut and the endocrine system do not operate independently. At the intersection sits a collection of bacterial genes known as the estrobolome - responsible for metabolising circulating oestrogen and returning it to active form. When the gut microbiome is disrupted, the estrobolome falters, accelerating hormonal decline in ways that amplify almost every symptom of menopause.
Microbiome diversity
Post-menopausal women show measurably lower gut bacterial diversity than pre-menopausal women - a shift now linked to inflammation, metabolic dysfunction, and reduced resilience.
Gut barrier integrity
Falling oestrogen weakens intestinal lining, increasing permeability. Bacteria associated with obesity and systemic inflammation proliferate, compounding symptoms throughout the body.
The brain–gut axis
Reduced Ruminococcus species - short-chain fatty acid producers with neuroactive properties - impair signalling along the gut–brain axis, contributing to mood disruption, brain fog, and cognitive decline.
Cardiovascular risk
Altered estrobolome function correlates with adverse cardiometabolic markers post-menopause. The gut is now recognised as an upstream driver of heart disease risk in ageing women.
Bone density
The gut–bone axis mediates calcium absorption and inflammatory signalling. Microbiome disruption post-menopause directly accelerates bone mineral density loss.
"The menopausal gut is not a secondary concern. It is the primary terrain. When oestrogen declines, you lose the microbial architecture that underpins inflammatory control, hormonal recycling, neurotransmitter synthesis, and metabolic regulation simultaneously. ID² is designed to address the foundational layer - to restore the conditions in which a woman's biology can regulate itself again. This is not symptomatic relief. This is systemic restoration."
- Professor Paul Clayton, Chief Scientific Advisor, LYMA
Why ID² addresses this problem
Most gut interventions treat symptoms. LYMA ID² is formulated to address the underlying biological disruption - across four distinct mechanisms.
Microbiome restoration
ID² is formulated to rebuild bacterial diversity - the core deficit in menopausal gut decline. Targeted prebiotic and probiotic compounds support the re-establishment of protective species including the Ruminococcus genus and Lactobacillus strains shown to reduce menopausal symptom severity.
Estrobolome support
By restoring the specific bacterial populations responsible for oestrogen metabolism, ID² supports the body's own hormonal regulation - not by adding hormones, but by reactivating the microbial infrastructure that processes them. To understand more about the science behind LYMA, including the peer-reviewed research underpinning ID², visit the science page.
Gut barrier integrity
Formulated to reduce intestinal permeability - the driver of systemic inflammation in menopause - ID² addresses the root cause of bloating, digestive discomfort, and the inflammatory cascade that accelerates wider menopausal health decline.
Whole-body downstream benefit
Because the gut governs bone metabolism, cardiovascular markers, cognitive function, and mood, a well-formulated gut intervention at menopause is not a single-symptom product. It is a systemic investment. This is the science ID² is built on - and it's why results extend far beyond the digestive system. For women exploring a comprehensive approach to midlife health, the LYMA Journal covers the full breadth of the science.
The case for acting now
The menopausal gut crisis is real, widespread, and almost entirely unmet by conventional medicine. For the 82% of women whose digestive health deteriorates at this life stage - and the 89% who are left to manage it alone - the science now exists to offer something genuinely different.
Explore LYMA ID² and the formulation built on this science.
Sources: The Menopause Society (2025) · Frontiers in Endocrinology (2025) · PMC / PubMed · ZOE Study · BMC Women's Health (2024)
